NEW YORK (GenomeWeb) – Illumina and molecular diagnostics firm Burning Rock announced today that they will codevelop oncology products based on Illumina's sequencing instruments for the Chinese market.
As part of the agreement, Illumina will provide NGS instrument components and reagents and Guangzhou, China-based Burning Rock will provide its nucleic acid extraction, library preparation, and data analysis software.
"We have been working to promote the clinical application of genomic technology in China," Burning Rock Founder and CEO Yusheng Han said in a statement. "Oncology molecular diagnosis based on NGS, including non-invasive testing, is being applied in the clinic and we hope to promote it as a standard practice in hospitals."
The collaboration will "increase access to oncology diagnosis solutions in China," Rick Klausner, Illumina's senior VP and chief medical officer, said in a statement.